Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Jain

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 17, 2018
Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancerCorrine Ying Xuan Chua, Priya Jain, Antonia Susnjar, et al.
Immunotherapy|March 31, 2025
Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO studySabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, et al.
The British Journal of Dermatology|February 17, 2024
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trialSabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|November 24, 2018
Nanofluidic microsystem for sustained intraocular delivery of therapeuticsNicola Di Trani, Priya Jain, Corrine Ying Xuan Chua, et al.
Biomedical Microdevices|June 20, 2018
Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case studyCarly S Filgueira, Giacomo Bruno, Zachary W Smith, et al.
Pediatric Emergency Care|November 3, 2021
Pediatric Emergency Medicine Fellowship Directors' 2021 Collective Statement on Virtual Interviews and Second LooksLauren Allister, Aline Baghdassarian, Derya Caglar, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 10, 2018
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxisCorrine Ying Xuan Chua, Priya Jain, Andrea Ballerini, et al.
Nature Medicine|May 5, 2026
Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Nature Medicine|March 31, 2026
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Indian Journal of Pediatrics|June 10, 2019
Association of Child Neurology-Indian Epilepsy Society Consensus Document on Parental Counseling of Children with EpilepsyKavita Srivastava, Rachna Sehgal, Ramesh Konanki, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 17, 2018
Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancerCorrine Ying Xuan Chua, Priya Jain, Antonia Susnjar, et al.
Immunotherapy|March 31, 2025
Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO studySabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, et al.
The British Journal of Dermatology|February 17, 2024
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trialSabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|November 24, 2018
Nanofluidic microsystem for sustained intraocular delivery of therapeuticsNicola Di Trani, Priya Jain, Corrine Ying Xuan Chua, et al.
Biomedical Microdevices|June 20, 2018
Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case studyCarly S Filgueira, Giacomo Bruno, Zachary W Smith, et al.
Pediatric Emergency Care|November 3, 2021
Pediatric Emergency Medicine Fellowship Directors' 2021 Collective Statement on Virtual Interviews and Second LooksLauren Allister, Aline Baghdassarian, Derya Caglar, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 10, 2018
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxisCorrine Ying Xuan Chua, Priya Jain, Andrea Ballerini, et al.
Nature Medicine|May 5, 2026
Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Nature Medicine|March 31, 2026
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Indian Journal of Pediatrics|June 10, 2019
Association of Child Neurology-Indian Epilepsy Society Consensus Document on Parental Counseling of Children with EpilepsyKavita Srivastava, Rachna Sehgal, Ramesh Konanki, et al.
Pageof 5